Thousands of lawsuits filed over the hypertension drug Benicar’s link to strange gastrointestinal symptoms have been settled for $300 million. New claims are still possible, but only for a limited time:
- Deadline: August 23, 2017
- Drugs: Benicar, Benicar HCT, Tribenzor, Azor
- Injuries: Celiac disease, sprue-like enteropathy
New claimants must retain counsel and complete the necessary paperwork by Wednesday, August 23, 2017 at 11:59 pm E.T. Don’t wait. Contact our experienced product liability lawyers now for a free consultation.
The Benicar settlement can help injured patients and families get back on their feet, but time is limited. We urge you to contact an experienced attorney immediately.
“So Grateful” I always felt like Laurence truly cared about my family’s future.[/fusion_testimonial][/fusion_testimonials]
Banville Law Reviewed by Catherine P. on February 16th.
Rating: 5.0 ★★★★★
Several law firms have begun to run television commercials, informing patients and their loved ones of a major Benicar settlement agreement announced by Japanese drug manufacturer Daiichi Sankyo. Did you see one of these TV commercials on a local station?
It’s all true. Daiichi Sankyo has officially settled nearly 2,300 Benicar lawsuits for a total of $300 million. The company is now establishing a settlement fund to administer claims related to gastrointestinal disorders, including celiac disease and sprue-like enteropathy.
New Benicar Claims Are Still Possible
For a limited time, new lawsuits will continue to be accepted. Patients and families who have not yet filed a Benicar claim still have time, but the deadline is approaching quickly.
After August 23, 2017, the Benicar settlement program will no longer accept new claims. Complying with this time limit is mandatory. New claimants have until August 23, 2017 at 11:59 pm E.T. to retain legal counsel and submit the proper documentation.
Don’t miss this one-time opportunity. If you or a loved one experienced gastrointestinal side effects after taking Benicar, contact our experienced product liability attorneys now for a free consultation. You owe us nothing until we secure an award in your case, but time is running out. The legal process must be started immediately to ensure that your rights are preserved.
Call today to learn more.
Thousands of patients and families may be entitled to significant financial compensation. Financial awards in the thousands of dollars are available to individuals who incurred medical expenses, lost wages and other damages as a result of alleged Benicar-related injuries.
Lawsuits Say Benicar Causes Severe Intestinal Issues
Pending lawsuits involve a number of drugs manufactured and sold by the Japanese corporation Daiichi Sankyo, including blockbuster blood pressure medications Benicar, Benicar HCT, Azor and Tribenzor. Medical studies indicate that these drugs, all based on the chemical olmesartan medoxomil, can lead to troubling gastrointestinal side effects, from nausea and vomiting to severe dehydration and weight loss. Thousands of patients have found themselves hospitalized, wracked by extreme abdominal pain and unable to nourish themselves.
Tragic deaths have also been reported.
Olmesartan & Sprue-Like Enteropathy
As experts at the US Food & Drug Administration report, there seems to be a link between olmesartan-based products and sprue-like enteropathy, a cluster of gastrointestinal symptoms that closely-resemble celiac disease. Symptoms of sprue-like enteropathy include:
- severe, persistent diarrhea
- abdominal pain
- nausea and vomiting
- unexplained weight loss
Sprue-like enteropathy is particularly dangerous because patients often lose the ability to nourish themselves properly. Severe weight loss and dehydration are common results.
Coordinated Litigation Leads To $300M Settlement
Daiichi Sankyo’s massive settlement offer comes after three years of protracted litigation. The first lawsuit to draw a link between olmesartan and sprue-like enteropathy was filed in 2014. Three years later, nearly 2,300 similar complaints had been consolidated in the US District Court of New Jersey. As a group, the claims went through pre-trial proceedings together, as plaintiffs’ attorneys prepared the cases for trial. Now, we know that the vast majority of these lawsuits will never reach a courtroom.
Representatives for Daiichi Sankyo and the plaintiffs have negotiated a $300 million settlement fund, which will begin paying out compensation awards in the near future. Titled the Olmesartan Products Resolution Program, this fund is structured to compensate patients and families who have already filed lawsuits, as well as claimants who have yet to step forward.
Who Can Secure Compensation?
Here’s a quick look at the settlement program’s eligibility requirements. In order to qualify for a Benicar settlement, claimants will have to demonstrate that they or their loved one:
- was prescribed Benicar, Benicar HCT, Azor or Tribenzor
- took the drug for 30 days or more
- began taking the drug on or before May 1, 2015
- suffered celiac disease, sprue-like enteropathy or associated gastrointestinal symptoms
To find a detailed overview of settlement eligibility, read our comprehensive guide to Benicar lawsuits here.
How Do We Learn More?
Looking for more information on the Benicar settlement program and your eligibility for compensation? Contact our experienced pharmaceutical attorneys today to receive a free confidential consultation. There’s no charge and no obligation, just the answers your family deserves. Remember: time is extremely limited. The opportunity to file an olmesartan claim will end on August 23, 2017. Don’t hesitate to find more details. Just call our lawyers now.